Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in PCI Inflammatory Marker Substudy
NCT01709981Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- May 2013
- Primary completion
- Aug 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary artery disease (CAD) comparing Colchicine with Placebo (2 arms). Primary endpoint: Interleukin-6 Concentration Percent Change. Started May 2013; status: completed.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01709981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709981.